Company intelligence / Profile preview

HealthLeap

Claymont, Delaware, United States

Ownership: Private
Employees: ~11
Development stage: Other

Overview

HealthLeap's NutriLeap platform demonstrates up to 88% higher sensitivity than traditional nurse-administered malnutrition screening and identifies patients with malnutrition up to 4 days earlier. It achieved AUROC values of 95% during patient stay and 91% on the first day in peer-reviewed retrospective validation studies with Cedars-Sinai, Johns Hopkins, and Stanford Health.

Therapeutic areas: CardiovascularOtherDermatologyMetabolic Disorders
Industry: Digital Health Medical Devices

Partnerships

Cedars-Sinai Accelerator

Beyond the preview

Go deeper on HealthLeap.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HealthLeap.

Explore the full profile